Aclaris Therapeutics ACRS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's financing cash flow?
- Aclaris Therapeutics (ACRS) reported financing cash flow of $57.78M in Q1 2026.
- How has Aclaris Therapeutics's financing cash flow changed year-over-year?
- Aclaris Therapeutics's financing cash flow increased by 21111.3% year-over-year, from -$275K to $57.78M.
- What is the long-term trend for Aclaris Therapeutics's financing cash flow?
- Over 2 years (2022 to 2025), Aclaris Therapeutics's financing cash flow has grown at a -71.6% compound annual growth rate (CAGR), from $72.88M to -$5.86M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.